The Drug Companies Avoiding Trump’s Tariffs — For Now

Generic medicines face no tariffs, though the Trump administration reserves the right to revisit that in the future. Some branded drugmakers face a reduced tariff rate, but that could change if they don’t reach a so-called most-favored nation drug price deal. The post The Drug Companies Avoiding Trump’s Tariffs — For Now appeared first on…

Read More

Why Biogen Is Paying $5.6B to Buy Apellis Pharma

Biogen’s Apellis Pharmaceuticals acquisition comes nearly two years after the drugmaker purchased immunology startup Human Immunology Biosciences. CEO Chris Viehbacher said Apellis accelerates Biogen’s expansion in nephrology, supporting a HI-Bio drug currently in pivotal testing for three kidney conditions. The post Why Biogen Is Paying $5.6B to Buy Apellis Pharma appeared first on MedCity News.

Read More